A woman undergoes radiotherapy. Credit: Unsplash/CC0 Public Domain

Authors: Corina Härning, University of Augsburg

Source: Medical Xpress

Many cancer patients develop severe dermatitis during radiotherapy. Which factors increase the risk of such radiodermatitis has only been partially understood up until now. A pilot study at the University of Augsburg, the Technical University of Munich (TUM), and Helmholtz Munich now points to the important role played by skin bacteria.

Radiotherapy is one of the most important weapons in the fight against cancer. It destroys tumour cells through high-energy radioactive radiation. Nevertheless, some patients tolerate treatment worse than others, with some patients developing severe skin inflammation—radiodermatitis—at the irradiated site. Until now, it was largely unclear why this only affected some of those treated.

The new study, published in the journal JAMA Oncology, now sheds some light on this, with the skin flora of the breast decisive in determining whether radiodermatitis occurs during the course of treatment. "The skin microbiome consists of hundreds of different kinds of microorganisms," explains Claudia Hülpüsch, head of functional microbiomics at the Chair for Environmental Medicine at the University of Augsburg.

"Some of them, the so-called commensal bacteria, are present in healthy people in a relative higher number and are part of the skin barrier. They act as natural protection, preventing the proliferation of harmful bacteria or fungi, for example."

Skin flora as a marker for increased risk of dermatitis

Together with her project partner Dr. Kai J. Borm from the University Hospital rechts der Isar at TUM, Hülpüsch examined 20 women with breast cancer. All patients received radiotherapy for a period of seven weeks. Before the first appointment and then each week thereafter the researchers took a skin swab from each patient—one from the breast treated with radiotherapy and one from the untreated breast. From the swabs, they were able to determine the number and composition of microorganisms.

"Through the analysis we determined that before beginning the radiotherapy four women had an unusual skin microbiome," explains Prof. Dr. Avidan Neumann from the Chair for Environmental Medicine at the University of Augsburg and researcher at Helmholtz Munich, who also participated in the study.

"With these women, commensal bacteria were underrepresented. This was the case for the healthy as well as for the diseased breast. Interestingly, each of these four patients developed severe radiodermatitis during the course of radiotherapy." In contrast, the other 16 patients only developed mild or moderate skin damage during radiotherapy.

In the first few weeks of therapy in the four patients with underrepresented commensal bacteria, the number of bacteria developed significantly before the development of visibly severe symptoms and then decreased again near the end of therapy. With the other patients, the bacteria remained largely unchanged. This leads to the suggestion that the bacteria play a causal role in the development of radiodermatitis.

Skin disinfection reduces the likelihood of dermatitis

"The composition of skin bacteria before radiotherapy appears to indicate which women have a particularly high risk of developing radiodermatitis," says Borm. "This helps in understanding this side-effect, enabling us to take targeted preventative measures to make radiotherapy more tolerable for patients in future."

Initial studies show that a thorough disinfection of the skin surface reduces the likelihood of subsequent inflammation. "We are also curious to find out if our results can be transferred to patients with other cancer types, such as those in the throat, nose, and ear, or with sarcomas, as these patients have a particularly high risk of severe radiodermatitis."

Prof. Dr. Claudia Traidl-Hoffmann, a dermatologist and director of the Chair for Environmental Medicine, sees great potential in the results and is already thinking about next steps. "We will now carry out larger studies with more patients with other tumours in order to verify the results. The goal is to be able to predict and prevent dermatitis, and this study has paved the way for this."

More information

This article was written by Corina Härning, University of Augsburg from Medical Xpress and was legally licensed through the DiveMarketplace by Industry Dive. Please direct all licensing questions to [email protected].

Medical Xpress Logo

Disclaimer: Novartis Ireland Limited accepts no responsibility for the content, accuracy, interpretation or out of use of the information contained within this article or its use of linked websites.

Rate this content: 
No votes yet
IE438012 | May 2024

Ask Speakers


Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.